Metraipolis › archive › dc_2f5edf03e642

Quantitative 3D histochemistry reveals region-specific amyloid-β reduction by the antidiabetic drug netoglitazone — Europe PMC PMID:40327707

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/40327707
DOI
10.1371/journal.pone.0309489
License (as archived)
CC0-1.0
Archived
2026-10-06T11:29:07.120Z
SHA-256 of the archived text
785d3a7a0bd1181e278e572ba0778d1c4e9a3f5dc228d6694dac2495ef338462
Stable URL of this page
https://metraipolis.com/documento/dc_2f5edf03e642

How to cite

Quantitative 3D histochemistry reveals region-specific amyloid-β reduction by the antidiabetic drug netoglitazone — Europe PMC PMID:40327707 — Europe PMC (en), https://europepmc.org/article/MED/40327707 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_2f5edf03e642 (Metraipolis archive dc_2f5edf03e642, sha256 785d3a7a0bd1181e278e572ba0778d1c4e9a3f5dc228d6694dac2495ef338462)
BibTeX
@misc{dc2f5edf03e642,
  title = {Quantitative 3D histochemistry reveals region-specific amyloid-β reduction by the antidiabetic drug netoglitazone — Europe PMC PMID:40327707},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40327707},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_2f5edf03e642; sha256 785d3a7a0bd1181e278e572ba0778d1c4e9a3f5dc228d6694dac2495ef338462},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/40327707. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

A hallmark of Alzheimer's disease (AD) is the extracellular aggregation of toxic amyloid-beta (Aβ) peptides in form of plaques. Here, we identify netoglitazone, an antidiabetic compound previously tested in humans, as an Aβ aggregation antagonist. Netoglitazone improved cognition and reduced microglia activity in a mouse model of AD. Using quantitative whole-brain three-dimensional histology (Q3D), we precisely identified brain regions where netoglitazone reduced the number and size of Aβ plaques. We demonstrate the utility of Q3D in preclinical drug evaluation for AD by providing a high-resolution brain-wide view of drug efficacy. Applying Q3D has the potential to improve pre-clinical drug evaluation by providing information that can help identify mechanisms leading to brain region-specific drug efficacy.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera).
Pubblicazione: PloS one, 2025 (prima pubblicazione 2025-05-06).
Identificativi: PMID 40327707 · PMCID PMC12054868 · DOI 10.1371/journal.pone.0309489.
Descrittori MeSH principali: Alzheimer Disease; Thiazolidinediones; Hypoglycemic Agents; Amyloid beta-Peptides.
Pagina: https://europepmc.org/article/MED/40327707 — https://doi.org/10.1371/journal.pone.0309489. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0.
Letto il 2026-10-06T09:52:29.944Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.